Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Editorial urges ’black-box’ warning for Bextra and Celebrex


Physicians should avoid prescribing Bextra altogether, or use it only as a drug of last resort, says a researcher from Wake Forest University Baptist Medical Center and colleagues in an editorial published on-line Jan. 17 in Circulation, a publication of the American Heart Association.

Curt D. Furberg, M.D., Ph.D., professor of public health sciences, and colleagues describe an analysis of two studies revealed that patients treated with Bextra after heart bypass surgery tripled their risk of heart attack and stroke compared to patients who received a placebo, or "dummy" drug. The data is a followup to information reported at the American Heart Association meeting in November.

"These data raise questions about the safety of the drug in other patients who have heart conditions, but who aren’t having surgery," said Furberg. "In the absence of evidence of safety, it is prudent to avoid the use of Bextra altogether or use it only as a drug of last resort," says the editorial. Furberg’s co-authors are Bruce M. Psaty, M.D., Ph.D., from the University of Washington in Seattle, and Garret A. FitzGerald, M.D., from the University of Pennsylvania.

The researchers say the Bextra results, combined with studies showing cardiovascular hazards with Celebrex and Vioxx, "provide compelling evidence that these adverse coronary and cerebrovascular events represent a class effect…" The drugs are all part of a class called COX-2 inhibitors. "A black-box warning that alerts practitioners to the potential cardiovascular hazards, especially in patients at moderate to high risk, seems timely for all COX-2 inhibitors," said Psaty.

Furberg supports the advice of the Food and Drug Administration, which issued a Public Health Advisory on COX-2 inhibitors and other non-steroidal anti-inflammatory drug products urging physicians to weigh the benefits against the risk for individual patients.

In the editorial, the authors support research to learn whether the drugs can be safely given for extended periods to patients at low risk of cardiovascular disease. "It is currently unclear to what degree the risk extends to patients treated with lower doses for arthritis because studies of sufficient size and duration have not been reported," Furberg said.

FitzGerald, who has been studying COX-2 inhibitors for more than six years, says that plans by Pfizer to study potential cardiovascular benefits of Celebrex are ill-advised.

In a separate article in Circulation, FitzGerald and colleagues report on evidence from mice showing that the combination of aspirin and a COX-2 inhibitor could make plaque in the arteries more likely to rupture and cause clotting, resulting in heart attack or stroke. "These results have disturbing implications for patients at high cardiovascular risk treated with aspirin and a COX inhibitor," writes FitzGerald.

Karen Richardson | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>